

Florian van BÄ¶mmel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8463691/publications.pdf>

Version: 2024-02-01

41
papers

7,121
citations

279798

23
h-index

265206

42
g-index

42
all docs

42
docs citations

42
times ranked

6183
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	4.4	9
2	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	3.7	48
3	Safety and effectiveness of up to 3 years [™] bulevirtide monotherapy in patients with HDV-related cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 464-469.	3.7	48
4	A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV [™] cure [™] . <i>Journal of Hepatology</i> , 2022, 77, 245-248.	3.7	29
5	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	3.7	59
6	Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA. <i>Seminars in Liver Disease</i> , 2022, 42, 327-340.	3.6	1
7	Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. <i>Pathogens</i> , 2022, 11, 517.	2.8	20
8	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C [™] Registry. <i>Hepatology Communications</i> , 2022, 6, 2488-2495.	4.3	6
9	Final safety and efficacy results from a 106 real [™] world patients registry with an ascites [™] mobilizing pump. <i>Liver International</i> , 2022, 42, 2247-2259.	3.9	4
10	Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 283-292.	3.7	35
11	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021, 72, 202-211.	5.8	41
12	Glecaprevir/pibrentasvir for 8 [™] weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C [™] Registry. <i>Liver International</i> , 2021, 41, 1518-1522.	3.9	9
13	Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg [™] Negative Chronic Hepatitis B. <i>Hepatology Communications</i> , 2021, 5, 1632-1648.	4.3	20
14	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	4.9	5
15	Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery. <i>PLoS ONE</i> , 2021, 16, e0254817.	2.5	10
16	The times they are a-changing [™] A refined proposal for finite HBV nucleos(t)ide analogue therapy. <i>Journal of Hepatology</i> , 2021, 75, 474-480.	3.7	46
17	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	6.1	11
18	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 314-320.	3.7	19

#	ARTICLE	IF	CITATIONS
19	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 733-744.	3.7	18
20	Ten millennia of hepatitis B virus evolution. <i>Science</i> , 2021, 374, 182-188.	12.6	64
21	Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. <i>CardioVascular and Interventional Radiology</i> , 2021, , 1.	2.0	5
22	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. <i>Liver International</i> , 2020, 40, 539-548.	3.9	24
23	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	3.7	69
24	Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 610-619.	2.0	21
25	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	3.7	75
26	Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	4
27	Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. <i>Liver International</i> , 2019, 39, 263-270.	3.9	7
28	Association of <scp>HLA</scp>-<scp>DPA</scp>1 and <scp>HLA</scp>-<scp>DPB</scp>1 polymorphisms with spontaneous <scp>HB</scp>sAg seroclearance in Caucasians. <i>Liver International</i> , 2019, 39, 646-654.	3.9	12
29	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. <i>Hepatology</i> , 2018, 68, 839-847.	7.3	72
30	Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 397-400.	7.3	36
31	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	3.7	88
32	Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with <scp>HB</scp>sAg-negative chronic hepatitis B. <i>Liver International</i> , 2018, 38, 90-96.	3.9	31
33	Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. <i>Gut</i> , 2018, 67, 2045-2053.	12.1	66
34	Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2018, 218, 1066-1074.	4.0	56
35	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 67, 370-398.	3.7	3,803
36	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	7.3	239

#	ARTICLE	IF	CITATIONS
37	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study. Journal of Hepatology, 2017, 67, 918-924.	3.7	230
38	Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 2015, 61, 66-76.	7.3	204
39	Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. Journal of Hepatology, 2014, 60, 928-933.	3.7	55
40	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. Antiviral Therapy, 2012, 17, 1049-1058.	1.0	15
41	Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine, 2005, 352, 2682-2695.	27.0	1,465